Suncross Pharmaceuticals Private Limited

Suncross Pharmaceuticals Private Limited - business services in Indore, Madhya Pradesh, India. Directors, charges & compliance details.
CIN U46497MP2023PTC065990 Incorporated 29 May 2023 ROC Gwalior HQ Indore, Madhya Pradesh, India
Active Private Limited Company
Revenue · FY 2025
₹14.88 Lakh
▲ 17% YoY
Net profit · FY 2025
₹38,090
Net margin 2.6%
EBITDA · FY 2025
₹49,219
EBITDA margin 3.3%
Authorised capital
₹10 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Company age
3 yrs
Est. 2023
Directors on board
3
As per MCA filings
Active GSTINs
1
GST registered

About Suncross Pharmaceuticals Private Limited

Data last updated:

Suncross Pharmaceuticals Private Limited is a private limited company based in Indore, Madhya Pradesh, India. It was incorporated on 29 May 2023.

The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN U46497MP2023PTC065990. Its GSTIN is 23ABKCS9344R1ZG (Madhya Pradesh).

The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Indresh Kumar Gupta and Shiv Shankar Gupta.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Indore, Madhya Pradesh.

As per the financials filed for FY 2025, the company reported a revenue of ₹14.88 Lakh, a growth of 17% compared to the previous year. For the same year it recorded a net profit of ₹38,090 (net margin 2.6%) and EBITDA of ₹49,219 (EBITDA margin 3.3%).

Company details

CIN U46497MP2023PTC065990
Registration Number 065990
Incorporation Date 29 May 2023
ROC Gwalior
Listing Status Unlisted
Company Status Active

Contact details

Suncross Pharmaceuticals Private Limited's registered office is in Indore, Madhya Pradesh.

  • Registered Address
    Plot No. 101 Second Floor Flat No 201, Limbodi, Indore, Madhya Pradesh, India – 452001
Comprehensive company report
Suncross Pharmaceuticals Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Suncross Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GWholesale and retail trade; repair of motor vehicles and motorcycles46Wholesale trade, except of motor vehicles and motorcycles

To see the full business activity and turnover split of Suncross Pharmaceuticals Private Limited, buy the company report.

Financials of Suncross Pharmaceuticals Private Limited

FY 2025 filings available

Suncross Pharmaceuticals Private Limited reported revenue of ₹14.88 Lakh (up 17% YoY) for FY 2025.

Revenue · FY 2025
₹14.88 Lakh ▲ 17%
Net profit · FY 2025
₹38,090 margin 2.6%
EBITDA · FY 2025
₹49,219 margin 3.3%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 17%
EBITDA CAGR growth
1 year
▲ 35%

Revenue rose 17% in the latest year. EBITDA rose 35% in the latest year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹49,219
Profit Before Tax
Tax Expense
Net Profit (PAT)₹38,090
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24
Profitability
EBITDA Margin3.3%
Net Profit Margin2.6%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Suncross Pharmaceuticals Private Limited, buy the company report.

Board of directors of Suncross Pharmaceuticals Private Limited

Suncross Pharmaceuticals has 3 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Indresh Kumar GuptaDirector29 May 20233 Years 5 MonthsCurrent
Shiv Shankar GuptaAdditional Director28 Aug 20251 Years 2 MonthsCurrent
Poornima DwivediAdditional Director28 Aug 20251 Years 2 MonthsCurrent

MSME payment delays

No delayed payments to MSME suppliers are on our record for Suncross Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Suncross Pharmaceuticals has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
23ABKCS9344R1ZGMadhya PradeshActive05 Jul 2023

To see the full GST registrations and return filing status of Suncross Pharmaceuticals Private Limited, buy the company report.

Recent activity

Suncross Pharmaceuticals Private Limited has 6 board changes on record since 2023: 4 appointments and 2 cessations. The latest: Poornima Dwivedi was appointed as Additional Director on 28 Aug 2025.

AGM
Suncross Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Appointed
Poornima Dwivedi was appointed as Additional Director.
Appointed
Shiv Shankar Gupta was appointed as Additional Director.
Ceased
Vidyakant Dwivedi ceased to be Director.
Filing
Suncross Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Gwalior.
Ceased
Radharaman Dwivedi ceased to be Director.
Appointed
Indresh Kumar Gupta was appointed as Director.
Appointed
Vidyakant Dwivedi was appointed as Director.
Incorporation
29 May 2023
Suncross Pharmaceuticals Private Limited was registered on 29 May 2023 with Roc Gwalior & aged 3 years 5 months as per MCA records.

Frequently asked questions

Suncross Pharmaceuticals is an active private limited company based in Indore, Madhya Pradesh, India. It was incorporated on 29 May 2023 (3+ years old) and is registered under CIN U46497MP2023PTC065990.

Suncross Pharmaceuticals has 3 current directors:

The latest financial statements of Suncross Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2024 are in the company report.

The GSTIN of Suncross Pharmaceuticals is 23ABKCS9344R1ZG, registered in Madhya Pradesh.

The CIN (Corporate Identification Number) of Suncross Pharmaceuticals is U46497MP2023PTC065990. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Suncross Pharmaceuticals was incorporated on 29 May 2023, making it 3+ years old. It is registered with the Registrar of Companies, Gwalior.

Poornima Dwivedi was appointed as Additional Director on 28 Aug 2025. Shiv Shankar Gupta was appointed as Additional Director on 28 Aug 2025. Vidyakant Dwivedi ceased to be Director on 28 Aug 2025. Suncross Pharmaceuticals has 6 board changes on record in total.

The registered office of Suncross Pharmaceuticals is at Plot No. 101 Second Floor Flat No 201, Limbodi, Indore, Madhya Pradesh, India – 452001.

Suncross Pharmaceuticals can be reached at its registered office: Plot No. 101 Second Floor Flat No 201, Limbodi, Indore, Madhya Pradesh, India – 452001.

Suncross Pharmaceuticals is registered under the jurisdiction of the Registrar of Companies (ROC), Gwalior.